ReviewPharmacogenomics and personalized medicine2015
Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR.
Review in Pharmacogenomics and personalized medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Article
- Impact of LKB1 status on radiation outcome in patients with stage III non-small-cell lung cancer.Scientific reports · 2024Article
- Evaluating clinical and radiomic features for predicting lung cancer recurrence pre- and post-tumor resection.Proceedings of SPIE--the International Society for Optical Engineering · 2024Article
- Myristoylated TMEM39AS41, a cell-permeable peptide, causes lung cancer cell death.Toxicological research · 2020Article
- RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer.Journal of cellular physiology · 2018Article
- Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01).Journal of pathology and translational medicine · 2018Article
- Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations.Journal of personalized medicine · 2018Article
- Article
- Mutational status ofOncotarget · 2017Article
- Familial Lung Cancer: A Brief History from the Earliest Work to the Most Recent Studies.Genes · 2017Review
- Active fraction (HS7) fromChinese medicine · 2017Article
- Analysis of Chromosome 3, 7 and 8 Centromeric Regions in Bronchial Lavage Specimens by FISH.Turkish thoracic journal · 2016Article
- KRAS AND THE REALITY OF PERSONALIZED MEDICINE IN NON-SMALL CELL LUNG CANCER.Molecular medicine (Cambridge, Mass.) · 2016Article
- On Predicting lung cancer subtypes using 'omic' data from tumor and tumor-adjacent histologically-normal tissue.BMC cancer · 2016Article
- The hallmarks of premalignant conditions: a molecular basis for cancer prevention.Seminars in oncology · 2016Review
- Clinical potential of gene mutations in lung cancer.Clinical and translational medicine · 2015Article
- Article
- Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges.Cancers · 2015Review
- Article
- Diagnostic, Prognostic, and Predictive Molecular Biomarkers and the Utility of Molecular Imaging in Common Gastrointestinal Tumors.BioMed research international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide. The application of next-generation genomic technologies has offered a more comprehensive look at the mutational landscape across the different subtypes of non-small cell lung cancer (NSCLC). A number of recurrent mutations such as TP53, KRAS, and epidermal growth factor receptor (EGFR) have been identified in NSCLC. While targeted therapeutic successes have been demonstrated in the therapeutic targeting of EGFR and ALK, the majority of NSCLC tumors do not harbor these genomic events. This review looks at the current treatment paradigms for lung adenocarcinomas and squamous cell carcinomas, examining genomic aberrations that dictate therapy selection, as well as novel therapeutic strategies for tumors harboring mutations in KRAS, TP53, and LKB1 which, to date, have been considered "undruggable". A more thorough understanding of the molecular alterations that govern NSCLC tumorigenesis, aided by next-generation sequencing, will lead to targeted therapeutic options expected to dramatically reduce the high mortality rate observed in lung cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.